We expect Vectura’s US partner Roxane Laboratories to file VR315 for approval as a directly substitutable generic Advair® product in the USA over the coming months, targeting the current c. $2.6bn branded Advair® market from 2017e. In addition, we believe Utibron® (Ultibro® outside the USA) could perform ahead of expectations post expected US launch in H1 2016. Our recommendation remains Buy with a TP of 209p.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
US product launches and VR315 filing ahead
- Published:
28 Jan 2016 -
Author:
Dr Jens Lindqvist -
Pages:
4
We expect Vectura’s US partner Roxane Laboratories to file VR315 for approval as a directly substitutable generic Advair® product in the USA over the coming months, targeting the current c. $2.6bn branded Advair® market from 2017e. In addition, we believe Utibron® (Ultibro® outside the USA) could perform ahead of expectations post expected US launch in H1 2016. Our recommendation remains Buy with a TP of 209p.